A UCLH patient with B-cell Non-Hodgkin Lymphoma (NHL) has been treated with an investigational cancer drug under clinical trial conditions.
This was the first patient in the UK to be enrolled onto a Phase I/II clinical trial which is evaluating an investigational targeted treatment for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.
The study is being delivered at the NIHR UCLH Clinical Research Facility.
NHL is the sixth most common cancer in the UK. More than 13,000 people are diagnosed each year, and around 5,000 people die from the disease annually. While survival has improved significantly over the past two decades, a substantial proportion of patients experience relapse or develop disease that does not respond to standard treatment.
For these patients, options can become increasingly limited, highlighting the urgent need for new therapeutic approaches.
NHL includes several subtypes such as diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. The trial is open to adults whose disease has returned after previous treatment.
The investigational drug is designed to deliver a potent anti-cancer payload directly inside B-cell lymphoma cells. This precision approach aims to maximise tumour cell killing while limiting damage to healthy tissue.
The trial will first evaluate the safety and tolerability of this investigational drug and determine the most appropriate dose. Later parts of the study may assess the drug in combination with other anti-cancer treatments.
Access more information about the trial.
Image in news feed: Adobe Stock / Johannes
Image below: Trial lead Dr Will Townsend (furthest right in the photo) with members of the research team from the Clinical Research Facility and the first trial participant in the centre.
